Meningococcal Disease Vaccine - Global and China Top Players Market Share and Ranking 2023
According to Market IntelliX Research, the global market for Meningococcal Disease Vaccine should grow from US$ million in 2024 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Meningococcal Disease Vaccine market should grow from US$ million in 2024 to US$ million by 2030, with a CAGR of % for the period of 2024-2030. The United States Meningococcal Disease Vaccine market should grow from US$ million in 2024 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.
By segment, Infant grew percent to account for percent of the total market sales, and Child grew percent.
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
This report studies and analyses global Meningococcal Disease Vaccine status and future trends, helps the client to determine the Meningococcal Disease Vaccine market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Meningococcal Disease Vaccine, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2024 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Meningococcal Disease Vaccine market size, history data 2019-2024, and forecast data 2024 -2030, (US$ million) & (K Units)
(2) Global Meningococcal Disease Vaccine sales, revenue, price by company, market share and industry ranking 2019-2024, (US$ million) & (K Units)
(3) China Meningococcal Disease Vaccine sales, revenue, price by company, market share and industry ranking 2019-2024, (US$ million) & (K Units)
(4) Global Meningococcal Disease Vaccine key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Meningococcal Disease Vaccine key producing regions, capacity, production, and year over year growth
(6) Meningococcal Disease Vaccine industry chains, upstream, midstream and downstream
Market segment by players, this report covers
AstraZeneca
Johnson & Johnson
Mylan N.V
Teva Pharmaceutical Industries Ltd
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Baxter
BIO-MED
Bio-Manguinhos
Walvax Biotechnology Co., Ltd
Market segment by Type, covers
Polysaccharide
Conjugate
Combination
Market segment by Application, can be divided into
Infant
Child
Aldult
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Meningococcal Disease Vaccine product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global Meningococcal Disease Vaccine market share and ranking of major manufacturers, sales quantity, revenue, average price, 2019-2024
Chapter 3: China Meningococcal Disease Vaccine market share and ranking of major manufacturers, sales quantity, revenue, average price, 2019-2024
Chapter 4: Global key producing regions of Meningococcal Disease Vaccine, percent & CAGR, 2019-2030
Chapter 5: Meningococcal Disease Vaccine industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2019-2030
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2019-2030
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.
Chapter 11: Conclusions
1 Market Overview
1.1 Meningococcal Disease Vaccine Definition
1.2 Global Meningococcal Disease Vaccine Market Size and Forecast
1.2.1 By Consumption Value, Global Meningococcal Disease Vaccine Market Size，2019-2030
1.2.2 By Sales Quantity, Global Meningococcal Disease Vaccine Market Size，2019-2030
1.2.3 Global Meningococcal Disease Vaccine Average Selling Price (ASP)，2019-2030
1.3 China Meningococcal Disease Vaccine Market Size and Forecast
1.3.1 By Consumption Value, China Meningococcal Disease Vaccine Market Size，2019-2030
1.3.2 By Sales Quantity, China Meningococcal Disease Vaccine Market Size，2019-2030
1.3.3 China Meningococcal Disease Vaccine Average Selling Price (ASP)， 2019-2030
1.4 Share of China Meningococcal Disease Vaccine Market with Respect to the Global Market
1.4.1 By Consumption Value, China Meningococcal Disease Vaccine Market Share in Global, 2019-2030
1.4.2 By Sales Quantity, China Meningococcal Disease Vaccine Market Share in Global, 2019-2030
1.4.3 Meningococcal Disease Vaccine Market Size: China VS Global, 2019-2030
1.5 Meningococcal Disease Vaccine Market Dynamics
1.5.1 Meningococcal Disease Vaccine Market Drivers
1.5.2 Meningococcal Disease Vaccine Market Restraints
1.5.3 Meningococcal Disease Vaccine Industry Trends
1.5.4 Meningococcal Disease Vaccine Industry Policy
2 Global Leading Manufacturers and Market Share
2.1 By Revenue of Meningococcal Disease Vaccine, Global Market Share by Company, 2019-2024
2.2 By Sales Quantity of Meningococcal Disease Vaccine, Global Market Share by Company, 2019-2024
2.3 Meningococcal Disease Vaccine Average Selling Price (ASP) by Company, 2019-2024
2.4 Global Meningococcal Disease Vaccine Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Meningococcal Disease Vaccine Concentration Ratio
2.6 Global Meningococcal Disease Vaccine Mergers & Acquisitions, Expansion Plans
2.7 Global Meningococcal Disease Vaccine Manufacturers Product Type
2.8 Head Office and Meningococcal Disease Vaccine Production Site of Key Manufacturer
2.9 Meningococcal Disease Vaccine Capacity of Major Manufacturers and Future Plan
3 China Leading Manufacturers and Market Share
3.1 By Revenue of Meningococcal Disease Vaccine, China Market Share by Company, 2019-2024
3.2 By Sales Quantity of Meningococcal Disease Vaccine, China Market Share by Company, 2019-2024
3.3 China Meningococcal Disease Vaccine Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Global Producing Regions
4.1 Global Meningococcal Disease Vaccine Capacity, Output and Capacity Utilization, 2019-2030
4.2 Global Meningococcal Disease Vaccine Capacity by Region
4.3 Global Meningococcal Disease Vaccine Production & Forecast by Region, 2019 VS 2024 VS 2030
4.4 Global Meningococcal Disease Vaccine Production by Region, 2019-2030
4.5 Global Meningococcal Disease Vaccine Production Market Share & Forecast by Region, 2019-2030
5 Industry Chain Analysis
5.1 Meningococcal Disease Vaccine Industry Chain
5.2 Meningococcal Disease Vaccine Upstream Analysis
5.2.1 Meningococcal Disease Vaccine Core Raw Materials
5.2.2 Main Manufacturers of Meningococcal Disease Vaccine Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Meningococcal Disease Vaccine Production Mode
5.6 Meningococcal Disease Vaccine Procurement Model
5.7 Meningococcal Disease Vaccine Industry Sales Model and Sales Channels
5.7.1 Meningococcal Disease Vaccine Sales Model
5.7.2 Meningococcal Disease Vaccine Typical Distributors
6 Sights by Type
6.1 Meningococcal Disease Vaccine Classification
6.1.1 Polysaccharide
6.1.2 Conjugate
6.1.3 Combination
6.2 By Type, Global Meningococcal Disease Vaccine Consumption Value & CAGR, 2019 VS 2024 VS 2030
6.3 By Type, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030
6.4 By Type, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030
6.5 By Type, Global Meningococcal Disease Vaccine Average Selling Price (ASP), 2019-2030
7 Sights by Application
7.1 Meningococcal Disease Vaccine Segment by Application
7.1.1 Infant
7.1.2 Child
7.1.3 Aldult
7.2 By Application, Global Meningococcal Disease Vaccine Consumption Value & CAGR, 2019 VS 2024 VS 2030
7.3 By Application, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030
7.4 By Application, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030
7.5 By Application, Global Meningococcal Disease Vaccine Price, 2019-2030
8 Sales Sights by Region
8.1 By Region, Global Meningococcal Disease Vaccine Consumption Value, 2019 VS 2024 VS 2030
8.2 By Region, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030
8.3 By Region, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030
8.4 North America
8.4.1 North America Meningococcal Disease Vaccine & Forecasts, 2019-2030
8.4.2 By Country, North America Meningococcal Disease Vaccine Market Size Market Share
8.5 Europe
8.5.1 Europe Meningococcal Disease Vaccine Market Size & Forecasts, 2019-2030
8.5.2 By Country, Europe Meningococcal Disease Vaccine Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific Meningococcal Disease Vaccine Market Size & Forecasts, 2019-2030
8.6.2 By Country/Region, Asia Pacific Meningococcal Disease Vaccine Market Size Market Share
8.7 South America
8.7.1 South America Meningococcal Disease Vaccine Market Size & Forecasts, 2019-2030
8.7.2 By Country, South America Meningococcal Disease Vaccine Market Size Market Share
8.8 Middle East & Africa
9 Sales Sights by Country Level
9.1 By Country, Global Meningococcal Disease Vaccine Market Size & CAGR, 2019 VS 2024 VS 2030
9.2 By Country, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030
9.3 By Country, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030
9.4 U.S.
9.4.1 U.S. Meningococcal Disease Vaccine Market Size, 2019-2030
9.4.2 By Type, U.S. Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.4.3 By Application, U.S. Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.5 Europe
9.5.1 Europe Meningococcal Disease Vaccine Market Size, 2019-2030
9.5.2 By Type, Europe Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.5.3 By Application, Europe Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.6 China
9.6.1 China Meningococcal Disease Vaccine Market Size, 2019-2030
9.6.2 By Type, China Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.6.3 By Application, China Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.7 Japan
9.7.1 Japan Meningococcal Disease Vaccine Market Size, 2019-2030
9.7.2 By Type, Japan Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.7.3 By Application, Japan Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.8 South Korea
9.8.1 South Korea Meningococcal Disease Vaccine Market Size, 2019-2030
9.8.2 By Type, South Korea Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.8.3 By Application, South Korea Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.9 Southeast Asia
9.9.1 Southeast Asia Meningococcal Disease Vaccine Market Size, 2019-2030
9.9.2 By Type, Southeast Asia Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.9.3 By Application, Southeast Asia Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.10 India
9.10.1 India Meningococcal Disease Vaccine Market Size, 2019-2030
9.10.2 By Type, India Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.10.3 By Application, India Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.11 Middle East & Africa
9.11.1 Middle East & Africa Meningococcal Disease Vaccine Market Size, 2019-2030
9.11.2 By Type, Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
9.11.3 By Application, Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
10 Manufacturers Profile
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
10.1.2 AstraZeneca Meningococcal Disease Vaccine Models, Specifications, and Application
10.1.3 AstraZeneca Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.1.4 AstraZeneca Company Profile and Main Business
10.1.5 AstraZeneca Recent Developments
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
10.2.2 Johnson & Johnson Meningococcal Disease Vaccine Models, Specifications, and Application
10.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.2.4 Johnson & Johnson Company Profile and Main Business
10.2.5 Johnson & Johnson Recent Developments
10.3 Mylan N.V
10.3.1 Mylan N.V Company Information, Head Office, Market Area, and Industry Position
10.3.2 Mylan N.V Meningococcal Disease Vaccine Models, Specifications, and Application
10.3.3 Mylan N.V Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.3.4 Mylan N.V Company Profile and Main Business
10.3.5 Mylan N.V Recent Developments
10.4 Teva Pharmaceutical Industries Ltd
10.4.1 Teva Pharmaceutical Industries Ltd Company Information, Head Office, Market Area, and Industry Position
10.4.2 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Models, Specifications, and Application
10.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.4.4 Teva Pharmaceutical Industries Ltd Company Profile and Main Business
10.4.5 Teva Pharmaceutical Industries Ltd Recent Developments
10.5 Pfizer Inc
10.5.1 Pfizer Inc Company Information, Head Office, Market Area, and Industry Position
10.5.2 Pfizer Inc Meningococcal Disease Vaccine Models, Specifications, and Application
10.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.5.4 Pfizer Inc Company Profile and Main Business
10.5.5 Pfizer Inc Recent Developments
10.6 GlaxoSmithKline plc
10.6.1 GlaxoSmithKline plc Company Information, Head Office, Market Area, and Industry Position
10.6.2 GlaxoSmithKline plc Meningococcal Disease Vaccine Models, Specifications, and Application
10.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.6.4 GlaxoSmithKline plc Company Profile and Main Business
10.6.5 GlaxoSmithKline plc Recent Developments
10.7 Novartis AG
10.7.1 Novartis AG Company Information, Head Office, Market Area, and Industry Position
10.7.2 Novartis AG Meningococcal Disease Vaccine Models, Specifications, and Application
10.7.3 Novartis AG Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.7.4 Novartis AG Company Profile and Main Business
10.7.5 Novartis AG Recent Developments
10.8 Sanofi
10.8.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
10.8.2 Sanofi Meningococcal Disease Vaccine Models, Specifications, and Application
10.8.3 Sanofi Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.8.4 Sanofi Company Profile and Main Business
10.8.5 Sanofi Recent Developments
10.9 Merck & Co., Inc.
10.9.1 Merck & Co., Inc. Company Information, Head Office, Market Area, and Industry Position
10.9.2 Merck & Co., Inc. Meningococcal Disease Vaccine Models, Specifications, and Application
10.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.9.4 Merck & Co., Inc. Company Profile and Main Business
10.9.5 Merck & Co., Inc. Recent Developments
10.10 F. Hoffmann-La Roche Ltd
10.10.1 F. Hoffmann-La Roche Ltd Company Information, Head Office, Market Area, and Industry Position
10.10.2 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Models, Specifications, and Application
10.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.10.4 F. Hoffmann-La Roche Ltd Company Profile and Main Business
10.10.5 F. Hoffmann-La Roche Ltd Recent Developments
10.11 Baxter
10.11.1 Baxter Company Information, Head Office, Market Area, and Industry Position
10.11.2 Baxter Meningococcal Disease Vaccine Models, Specifications, and Application
10.11.3 Baxter Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.11.4 Baxter Company Profile and Main Business
10.11.5 Baxter Recent Developments
10.12 BIO-MED
10.12.1 BIO-MED Company Information, Head Office, Market Area, and Industry Position
10.12.2 BIO-MED Meningococcal Disease Vaccine Models, Specifications, and Application
10.12.3 BIO-MED Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.12.4 BIO-MED Company Profile and Main Business
10.12.5 BIO-MED Recent Developments
10.13 Bio-Manguinhos
10.13.1 Bio-Manguinhos Company Information, Head Office, Market Area, and Industry Position
10.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Models, Specifications, and Application
10.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.13.4 Bio-Manguinhos Company Profile and Main Business
10.13.5 Bio-Manguinhos Recent Developments
10.14 Walvax Biotechnology Co., Ltd
10.14.1 Walvax Biotechnology Co., Ltd Company Information, Head Office, Market Area, and Industry Position
10.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Models, Specifications, and Application
10.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales Quantity, Revenue, Price and Gross Margin, 2019-2024
10.14.4 Walvax Biotechnology Co., Ltd Company Profile and Main Business
10.14.5 Walvax Biotechnology Co., Ltd Recent Developments
11 Conclusion
12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer
Table 1. Meningococcal Disease Vaccine Consumption Value & CAGR: China VS Global, 2019-2030, US$ Million
Table 2. Meningococcal Disease Vaccine Market Restraints
Table 3. Meningococcal Disease Vaccine Market Trends
Table 4. Meningococcal Disease Vaccine Industry Policy
Table 5. Global Meningococcal Disease Vaccine Revenue by Company, 2019-2024, US$ million, Ranked Based on Revenue in 2024
Table 6. Global Meningococcal Disease Vaccine Revenue Share by Company, 2019-2024, Ranked by Data of 2024
Table 7. Global Meningococcal Disease Vaccine Sales Quantity by Company, (2019-2024) & (K Units), Ranked Based on Sales in 2024
Table 8. Global Meningococcal Disease Vaccine Sales Quantity by Company, 2019-2024, Ranked by Data of 2024
Table 9. Global Meningococcal Disease Vaccine Average Selling Price (ASP) by Company, (2019-2024) & (US$/Unit)
Table 10. Global Meningococcal Disease Vaccine Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 11. Global Meningococcal Disease Vaccine Mergers & Acquisitions, Expansion Plans
Table 12. Global Meningococcal Disease Vaccine Manufacturers Product Type
Table 13. Head Office and Meningococcal Disease Vaccine Production Site of Key Manufacturer
Table 14. Meningococcal Disease Vaccine Capacity of Major Manufacturers and Future Plan
Table 15. China Meningococcal Disease Vaccine Revenue by Company, 2019-2024, US$ million, Ranked Based on Revenue in 2024
Table 16. China Meningococcal Disease Vaccine Sales Quantity by Company, (2019-2024) & (K Units), Ranked Based on Sales in 2024
Table 17. China Meningococcal Disease Vaccine Sales Quantity by Company, 2019-2024, Ranked by Data of 2024
Table 18. Global Meningococcal Disease Vaccine Production & Forecast by Region, 2019 VS 2024 VS 2030, (K Units)
Table 19. Global Meningococcal Disease Vaccine Production by Region, 2019-2024, (K Units)
Table 20. Global Meningococcal Disease Vaccine Production Forecast by Region, 2024-2030, (K Units)
Table 21. Global Key Players of Meningococcal Disease Vaccine Upstream (Raw Materials)
Table 22. Global Meningococcal Disease Vaccine Typical Customers
Table 23. Meningococcal Disease Vaccine Typical Distributors
Table 24. By Type, Global Meningococcal Disease Vaccine Consumption Value & CAGR, 2019 VS 2024 VS 2030, US$ Million
Table 25. By Application, Global Meningococcal Disease Vaccine Consumption Value & CAGR, 2019 VS 2024 VS 2030, US$ Million
Table 26. By Region, Global Meningococcal Disease Vaccine Consumption Value, 2019 VS 2024 VS 2030, US$ Million
Table 27. By Region, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030, US$ Million
Table 28. By Region, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Table 29. By Country, Global Meningococcal Disease Vaccine Consumption Value & CAGR, 2019 VS 2024 VS 2030, US$ Million
Table 30. By Country, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030, US$ Million
Table 31. By Country, Global Meningococcal Disease Vaccine Consumption Value Market Share, 2019-2030
Table 32. By Country, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Table 33. By Country, Global Meningococcal Disease Vaccine Sales Quantity Market Share, 2019-2030
Table 34. AstraZeneca Company Information, Head Office, Market Area, and Industry Position
Table 35. AstraZeneca Meningococcal Disease Vaccine Models, Specifications, and Application
Table 36. AstraZeneca Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 37. AstraZeneca Company Profile and Main Business
Table 38. AstraZeneca Recent Developments
Table 39. Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
Table 40. Johnson & Johnson Meningococcal Disease Vaccine Models, Specifications, and Application
Table 41. Johnson & Johnson Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 42. Johnson & Johnson Company Profile and Main Business
Table 43. Johnson & Johnson Recent Developments
Table 44. Mylan N.V Company Information, Head Office, Market Area, and Industry Position
Table 45. Mylan N.V Meningococcal Disease Vaccine Models, Specifications, and Application
Table 46. Mylan N.V Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 47. Mylan N.V Company Profile and Main Business
Table 48. Mylan N.V Recent Developments
Table 49. Teva Pharmaceutical Industries Ltd Company Information, Head Office, Market Area, and Industry Position
Table 50. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Models, Specifications, and Application
Table 51. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 52. Teva Pharmaceutical Industries Ltd Company Profile and Main Business
Table 53. Teva Pharmaceutical Industries Ltd Recent Developments
Table 54. Pfizer Inc Company Information, Head Office, Market Area, and Industry Position
Table 55. Pfizer Inc Meningococcal Disease Vaccine Models, Specifications, and Application
Table 56. Pfizer Inc Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 57. Pfizer Inc Company Profile and Main Business
Table 58. Pfizer Inc Recent Developments
Table 59. GlaxoSmithKline plc Company Information, Head Office, Market Area, and Industry Position
Table 60. GlaxoSmithKline plc Meningococcal Disease Vaccine Models, Specifications, and Application
Table 61. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 62. GlaxoSmithKline plc Company Profile and Main Business
Table 63. GlaxoSmithKline plc Recent Developments
Table 64. Novartis AG Company Information, Head Office, Market Area, and Industry Position
Table 65. Novartis AG Meningococcal Disease Vaccine Models, Specifications, and Application
Table 66. Novartis AG Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 67. Novartis AG Company Profile and Main Business
Table 68. Novartis AG Recent Developments
Table 69. Sanofi Company Information, Head Office, Market Area, and Industry Position
Table 70. Sanofi Meningococcal Disease Vaccine Models, Specifications, and Application
Table 71. Sanofi Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 72. Sanofi Company Profile and Main Business
Table 73. Sanofi Recent Developments
Table 74. Merck & Co., Inc. Company Information, Head Office, Market Area, and Industry Position
Table 75. Merck & Co., Inc. Meningococcal Disease Vaccine Models, Specifications, and Application
Table 76. Merck & Co., Inc. Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 77. Merck & Co., Inc. Company Profile and Main Business
Table 78. Merck & Co., Inc. Recent Developments
Table 79. F. Hoffmann-La Roche Ltd Company Information, Head Office, Market Area, and Industry Position
Table 80. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Models, Specifications, and Application
Table 81. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 82. F. Hoffmann-La Roche Ltd Company Profile and Main Business
Table 83. F. Hoffmann-La Roche Ltd Recent Developments
Table 84. Baxter Company Information, Head Office, Market Area, and Industry Position
Table 85. Baxter Meningococcal Disease Vaccine Models, Specifications, and Application
Table 86. Baxter Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 87. Baxter Company Profile and Main Business
Table 88. Baxter Recent Developments
Table 89. BIO-MED Company Information, Head Office, Market Area, and Industry Position
Table 90. BIO-MED Meningococcal Disease Vaccine Models, Specifications, and Application
Table 91. BIO-MED Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 92. BIO-MED Company Profile and Main Business
Table 93. BIO-MED Recent Developments
Table 94. Bio-Manguinhos Company Information, Head Office, Market Area, and Industry Position
Table 95. Bio-Manguinhos Meningococcal Disease Vaccine Models, Specifications, and Application
Table 96. Bio-Manguinhos Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 97. Bio-Manguinhos Company Profile and Main Business
Table 98. Bio-Manguinhos Recent Developments
Table 99. Walvax Biotechnology Co., Ltd Company Information, Head Office, Market Area, and Industry Position
Table 100. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Models, Specifications, and Application
Table 101. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2019-2024
Table 102. Walvax Biotechnology Co., Ltd Company Profile and Main Business
Table 103. Walvax Biotechnology Co., Ltd Recent Developments
List of Figures
Figure 1. Meningococcal Disease Vaccine Picture
Figure 2. Global Meningococcal Disease Vaccine Consumption Value, (US$ million) & (2019-2030)
Figure 3. Global Meningococcal Disease Vaccine Sales Quantity, (K Units) & (2019-2030)
Figure 4. Global Meningococcal Disease Vaccine Average Selling Price (ASP), (2019-2030) & (US$/Unit)
Figure 5. China Meningococcal Disease Vaccine Consumption Value, (US$ million) & (2019-2030)
Figure 6. China Meningococcal Disease Vaccine Sales Quantity (K Units) & (2019-2030)
Figure 7. China Meningococcal Disease Vaccine Average Selling Price (ASP), (US$/Unit) & (2019-2030)
Figure 8. By Consumption Value, China Meningococcal Disease Vaccine Market Share of Global, 2019-2030
Figure 9. By Sales Quantity, China Meningococcal Disease Vaccine Market Share of Global, 2019-2030
Figure 10. Global Meningococcal Disease Vaccine Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2024
Figure 11. China Meningococcal Disease Vaccine Key Participants, Market Share, 2024
Figure 12. Global Meningococcal Disease Vaccine Capacity, Production and Capacity Utilization, 2019-2030
Figure 13. Global Meningococcal Disease Vaccine Capacity Market Share by Region, 2024 VS 2030
Figure 14. Global Meningococcal Disease Vaccine Production Market Share & Forecast by Region, 2019-2030
Figure 15. Meningococcal Disease Vaccine Industry Chain
Figure 16. Meningococcal Disease Vaccine Procurement Model
Figure 17. Meningococcal Disease Vaccine Sales Model
Figure 18. Meningococcal Disease Vaccine Sales Channels, Direct Sales, and Distribution
Figure 19. Polysaccharide
Figure 20. Conjugate
Figure 21. Combination
Figure 22. By Type, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030, US$ Million
Figure 23. By Type, Global Meningococcal Disease Vaccine Consumption Value Market Share, 2019-2030
Figure 24. By Type, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 25. By Type, Global Meningococcal Disease Vaccine Sales Quantity Market Share, 2019-2030
Figure 26. By Type, Global Meningococcal Disease Vaccine Average Selling Price (ASP), 2019-2030, (US$/Unit)
Figure 27. Infant
Figure 28. Child
Figure 29. Aldult
Figure 30. By Application, Global Meningococcal Disease Vaccine Consumption Value, 2019-2030, US$ Million
Figure 31. By Application, Global Meningococcal Disease Vaccine Consumption Value Market Share, 2019-2030
Figure 32. By Application, Global Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 33. By Application, Global Meningococcal Disease Vaccine Sales Quantity Market Share, 2019-2030
Figure 34. By Application, Global Meningococcal Disease Vaccine Average Selling Price (ASP), 2019-2030, (US$/Unit)
Figure 35. By Region, Global Meningococcal Disease Vaccine Consumption Value Market Share, 2019-2030
Figure 36. By Region, Global Meningococcal Disease Vaccine Sales Quantity Market Share, 2019-2030
Figure 37. North America Meningococcal Disease Vaccine Consumption Value & Forecasts, 2019-2030, US$ Million
Figure 38. By Country, North America Meningococcal Disease Vaccine Consumption Value Market Share, 2024
Figure 39. Europe Meningococcal Disease Vaccine Consumption Value & Forecasts, 2019-2030, US$ Million
Figure 40. By Country, Europe Meningococcal Disease Vaccine Consumption Value Market Share, 2024
Figure 41. Asia Pacific Meningococcal Disease Vaccine Consumption Value & Forecasts, 2019-2030, US$ Million
Figure 42. By Country/Region, Asia Pacific Meningococcal Disease Vaccine Consumption Value Market Share, 2024
Figure 43. South America Meningococcal Disease Vaccine Consumption Value & Forecasts, 2019-2030, US$ Million
Figure 44. By Country, South America Meningococcal Disease Vaccine Consumption Value Market Share, 2024
Figure 45. Middle East & Africa Meningococcal Disease Vaccine Consumption Value & Forecasts, 2019-2030, US$ Million
Figure 46. U.S. Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 47. By Type, U.S. Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 48. By Application, U.S. Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 49. Europe Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 50. By Type, Europe Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 51. By Application, Europe Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 52. China Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 53. By Type, China Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 54. By Application, China Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 55. Japan Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 56. By Type, Japan Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 57. By Application, Japan Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 58. South Korea Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 59. By Type, South Korea Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 60. By Application, South Korea Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 61. Southeast Asia Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 62. By Type, Southeast Asia Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 63. By Application, Southeast Asia Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 64. India Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 65. By Type, India Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 66. By Application, India Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity, 2019-2030, (K Units)
Figure 68. By Type, Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 69. By Application, Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share, 2024 VS 2030
Figure 70. Research Methodology
Figure 71. Breakdown of Primary Interviews
Figure 72. Bottom-up and Top-down Approaches
Figure 73. Top-down Approaches
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|